Goldman Sachs’s InVivo Therapeutics Holdings Corp NVIV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-23,741
| Closed | -$5.22K | – | 6081 |
|
|
2024
Q1 | $5.22K | Buy |
+23,741
| New | +$15.2K | ﹤0.01% | 5454 |
|
|
2021
Q3 | – | Sell |
-1,605
| Closed | -$30K | – | 6771 |
|
|
2021
Q2 | $30K | Buy |
+1,605
| New | +$30.6K | ﹤0.01% | 6124 |
|
|
2018
Q1 | – | Sell |
-4
| Closed | -$57K | – | 6644 |
|
|
2017
Q4 | $57K | Hold |
4
| – | – | ﹤0.01% | 5917 |
|
|
2017
Q3 | $108K | Sell |
4
-5
| -56% | -$154K | ﹤0.01% | 6033 |
|
|
2017
Q2 | $452K | Buy |
9
+5
| +125% | +$273K | ﹤0.01% | 5173 |
|
|
2017
Q1 | $277K | Sell |
4
-2
| -33% | -$162K | ﹤0.01% | 5525 |
|
|
2016
Q4 | $440K | Sell |
6
-5
| -45% | -$447K | ﹤0.01% | 5163 |
|
|
2016
Q3 | $1.36M | Sell |
11
-7
| -39% | -$873K | ﹤0.01% | 4131 |
|
|
2016
Q2 | $1.93M | Sell |
18
-1
| -5% | -$118K | ﹤0.01% | 3651 |
|
|
2016
Q1 | $2.44M | Buy |
19
+14
| +280% | +$1.5M | ﹤0.01% | 3298 |
|
|
2015
Q4 | $684K | Buy |
5
+3
| +150% | +$446K | ﹤0.01% | 4648 |
|
|
2015
Q3 | $379K | Buy |
2
+1
| +100% | +$234K | ﹤0.01% | 5411 |
|
|
2015
Q2 | $183K | Buy |
+1
| New | +$264K | ﹤0.01% | 6214 |
|
Goldman Sachs's NVIV Position: Q2 2024 in Review
Goldman Sachs sold out of InVivo Therapeutics Holdings Corp (NVIV) in Q2 2024, closing a stake of 23,741 shares — an estimated $5.22K sold.
Goldman Sachs first reported a position in NVIV in Q2 2015 and held it in 13 quarters. The position peaked at $2.44M in Q1 2016. 0 funds tracked by Wall St. Rank hold NVIV as of Q2 2024.
- Goldman Sachs reported no remaining InVivo Therapeutics Holdings Corp position as of Q2 2024 after selling out during the quarter.
- Goldman Sachs sold 23,741 InVivo Therapeutics Holdings Corp shares in Q2 2024, an estimated $5.22K.
- Goldman Sachs first reported a position in InVivo Therapeutics Holdings Corp in Q2 2015 and held it in 13 quarters.
- Goldman Sachs's InVivo Therapeutics Holdings Corp position peaked at $2.44M in Q1 2016.
- 0 funds tracked by Wall St. Rank held InVivo Therapeutics Holdings Corp as of Q2 2024.
Based on Goldman Sachs's 13F filing for Q2 2024, filed 13 Aug 2024.